In contrast, a high dose of oral cholecalciferol supplementation in non-diabetic patients with chronic kidney disease stages 3–4 showed insignificantly reduced levels of Ang-2 and no changes in other angiogenic markers, including Ang-1, vascular endothelial growth factor receptor (VEGFR), VEGF, and tyrosine kinase receptor-2 after 16 weeks [64]. The gene discussed is VEGFA; the disease is chronic kidney disease.